Garry A Neil

Title: Garry A Neil: Innovator in ADHD Diagnosis and Treatment

Introduction

Garry A Neil is a notable inventor based in Haverford, PA, who has made significant contributions to the field of medicine, particularly in the diagnosis and treatment of Attention Deficit Hyperactivity Disorder (ADHD). His innovative work focuses on identifying biomarkers that can predict treatment efficacy, which is crucial for improving patient outcomes.

Latest Patents

Garry A Neil holds a patent titled "Methods of diagnosing and treating ADHD in biomarker positive subjects." This patent discloses the identification of a subset of mGluR network gene copy number variations (CNVs) that are predictive of the efficacy of treatment with fasoracetam. Additionally, it highlights an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD and certain associated symptoms. This groundbreaking work has the potential to transform how ADHD is diagnosed and treated.

Career Highlights

Garry A Neil is affiliated with The Children's Hospital of Philadelphia, where he applies his expertise in pediatric healthcare. His role at this esteemed institution allows him to work on innovative solutions that address the challenges faced by children with ADHD.

Collaborations

Garry collaborates with esteemed colleagues, including Liza Squires and Hakon Hakonarson, who share his commitment to advancing research in ADHD and related disorders. Their combined efforts contribute to a deeper understanding of the genetic factors involved in ADHD.

Conclusion

Garry A Neil's contributions to ADHD research through his patent and work at The Children's Hospital of Philadelphia exemplify the impact of innovation in medicine. His dedication to improving diagnosis and treatment for ADHD patients is commendable and highlights the importance of continued research in this vital area.